Noven gets hold rating from Jefferies

Noven Pharmaceuticals, Inc. was put on hold with a $25 price target by Jefferies & Co., Inc. analyst David Windley on the market's indifference about the company's earnings upside in the third quarter. The key to moving the stock is in greater pipeline disclosure, according to Windley. Noven's quarterly revenues were $1 million lower than the analyst's forecast. Due to manufacturing revenues related to Daytrana. Shares of the Miami-based drug delivery technology company were up 53 cents, or 2.36%, at $22.95. (Nasdaq: NOVN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.